Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-27T13:01:09.849Z Has data issue: false hasContentIssue false
  • English
  • Français

EPA-0775 – Efficacy of Lisdexamfetamine Dimesylate and Atomoxetine in Child and Adolescent Subgroups from a Head-Tohead, Double-Blind, Randomized Trial in Patients with Attention-Deficit/Hyperactivity Disorder

Published online by Cambridge University Press:  15 April 2020

R.W. Dittmann ,
E. Cardo ,
D.R. Coghill ,
P. Nagy ,
C.S. Anderson ,
B. Adeyi ,
B. Caballero ,
P. Hodgkins  and
R. Civil
R.W. Dittmann
Affiliation:
Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
E. Cardo
Affiliation:
Son Llàtzer Hospital and Research Institute on Health Sciences, University of the Balearic Islands, Palma de Mallorca, Spain
D.R. Coghill
Affiliation:
Division of Neuroscience, University of Dundee, Dundee, United Kingdom
P. Nagy
Affiliation:
Vadaskert Child and Adolescent Psychiatry Hospital and Outpatient Clinic, Vadaskert Child and Adolescent Psychiatry Hospital and Outpatient Clinic, Budapest, Hungary
C.S. Anderson
Affiliation:
Global Clinical Programs, Shire Development LLC, Wayne, United Kingdom
B. Adeyi
Affiliation:
Global Biostatistics, Shire Development LLC, Wayne, United Kingdom
B. Caballero
Affiliation:
Clinical Development and Medical Affairs, Shire AG, Eysins, Switzerland
P. Hodgkins
Affiliation:
Global Health Economics and Outcomes Research, Shire Development LLC, Wayne, United Kingdom
R. Civil
Affiliation:
Clinical Development and Medical Affairs, Shire Development LLC, Wayne, United Kingdom

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Symptoms of attention-deficit/hyperactivity disorder (ADHD) appear in childhood and may persist into adolescence and beyond.

Objective:

Evaluate the efficacy of lisdexamfetamine dimesylate (LDX) and atomoxetine in subgroups of children and adolescents with ADHD.

Methods:

In this 9-week, double-blind study, patients aged 6–17 with ADHD and an inadequate response to previous methylphenidate therapy were randomized (1:1) to optimized doses of LDX or atomoxetine. Efficacy measures included ADHD Rating Scale IV (ADHD-RS-IV) total score and dichotomized Clinical Global Impressions-Improvement (CGI-I) score (improved, 1–2; not improved, 3–7).

Results:

The full analysis set (n=262) comprised 194 children aged 6–12 (LDX, n=93; atomoxetine, n=101) and 68 adolescents aged 13–17 (LDX, n=34; atomoxetine, n=34). Mean optimized doses were: LDX, 52.5 (SD, 16.10) mg/day; atomoxetine, 40.2 (20.05) mg/day. Baseline mean ADHD-RS-IV total score was similar across treatment and age groups. Table shows efficacy results; safety profiles were consistent with previous studies.

 LDXAtomoxetine
Mean change in ADHD-RS-IV total score by visit 9 (95% confidence interval)
Overall−26.3 (−28.4, −24.2)−19.4 (−21.6, −17.2)
Children−27.5 (−29.8, −25.1)−19.4 (−22.0, −16.7)
Adolescents−22.9 (−27.3, −18.5)−19.5 (−23.7, −15.3)
Patients (%) with improved CGI-I score by visit 9 (95% confidence interval)
Overall81.7 (75.0, 88.5)63.6 (55.4, 71.8)
Children83.9 (76.4, 91.3)61.2 (51.6, 70.9)
Adolescents75.8 (61.1, 90.4)70.6 (55.3, 85.9)

Conclusion:

Within each treatment group, improvements in symptomatological scales and global improvement ratings were observed in children and adolescents.

Study funded by Shire.

Type
E06 - e-Poster Oral Session 06: Child Psychiatry and Personality Disorders
Information
European Psychiatry , Volume 29 , Issue S1: Abstracts of the 22nd European Congress of Psychiatry , 2014 , pp. 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.